|
Modifying Oxidative Damage in WAVE - Ancillary to WAVE Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Modifying Oxidative Damage in WAVE - Ancillary to WAVE conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Modifying Oxidative Damage in WAVE - Ancillary to WAVE Clinical research trials and Modifying Oxidative Damage in WAVE - Ancillary to WAVE healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Modifying Oxidative Damage in WAVE - Ancillary to WAVE. Modifying Oxidative Damage in WAVE - Ancillary to WAVE Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Modifying Oxidative Damage in WAVE - Ancillary to WAVE clinical trial. Human subjects often receive the most effective healthcare possible for their Modifying Oxidative Damage in WAVE - Ancillary to WAVE condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Modifying Oxidative Damage in WAVE - Ancillary to WAVE  Modifying Oxidative Damage in WAVE - Ancillary to WAVE
Modifying Oxidative Damage in WAVE - Ancillary to WAVE
For Condition: Coronary Disease,Cardiovascular Diseases,Heart Diseases
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the effects of four treatments (placebo, a vitamin E and C regimen, a hormone replacement regimen, and a combined vitamin/hormone replacement regimen) on specific markers of oxidative damage in coronary arteries of postmenopausal women.
Details: BACKGROUND: Supplemental vitamin E has been associated with a reduced risk of recurrent myocardial infarctions, with efficacy related to dosage and the duration of treatment. Its effects may be enhanced by vitamin C, an antioxidant that can regenerate vitamin E activity. Theoretically vitamin E and C (VitE/C) accumulate in the vascular wall with a concurrent reduction in oxidative damage, a primary feature of atherosclerotic lesions. Estrogen/hormone replacement therapy (HRT) also may reduce oxidative damage, and it may enhance the effect of vitamin E and C. These hypotheses are supported by studies defining oxidation-dependent accumulation of lipids in developing atherosclerosis; the detection of oxidative damage products, such as oxidized-LDL particles, in human atherosclerotic lesions; and clinical studies associating antioxidant or estrogen supplementation with reductions in oxidative damage cardiovascular disease. Nevertheless, no human studies have evaluated the effect of long-term VitE/C treatment, which has been reported as being the most effective prevention factor by epidemiologic studies, on specific. biochemical markers of oxidative damage and concurrently their association with recurrent cardiovascular disease. In addition, no studies have characterized the effect of long-term HRT on markers of oxidative damage or HRT's potential synergistic effect with VitE/C therapy. DESIGN NARRATIVE: The study assayed specific biochemical measures of oxidative damage (all markers at closeout and nitrotyrosine and chlorotyrosine also at baseline) in the Women's Angiographic Vitamin and Estrogen (WAVE) Trial, which randomized 420 38-86 year old women with a prior cardiovascular disease event to placebo, Vitamin E/C, hormone replacement therapy (HRT) or the combination of VitE/C and HRT. WAVE determined the efficacy of these treatments on quantitative angiographic evaluation of minimal coronary artery diameter performed at baseline and at the final visit to be completed during the first 10 months of 2001. The ancillary study measured oxidation products from several classes of compounds (lipids by F2-isoprostanes, proteins by nitrotyrosine and chlorotyrosine, and DNA by 8-hydroxy-2'-deoxyguanosine), thereby studying several major pathways that may lead to atherogenesis. In addition, inflammation with C-reactive protein, platelet activation with p-selectin, altered lipid metabolism with a lipid profile and other characteristics of the study population were integrated into the assessment of oxidative damage in WAVE. By measuring these various factors and by assessing oxidative damage in several classes of compounds, the authors tested the relationships among specific pathways of oxidative damage, supplemental VitE/C and/or HRT and other risk factors upon the progression of established macrovascular disease.
Eligibility:
Study Type: Observational, Longitudinal, Retrospective Study
Minimum Age/Maximum Age: 38 Years/86 Years
Genders: Female
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelSteffes, , University of Minnesota
Additional Information:
Study ID Numbers: 979;
Study Start Date: April 2001
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00021970
Other Coronary Disease Studies:
1. Seasonal Variation of Blood Cholesterol Levels
2. Coronary Heart Disease Risk Factors in Blacks Vs Whites
3. Program on Surgical Control of Hyperlipidemias (POSCH)
4. Visceral Adiposity and CVD Risk in Women
5. Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)
Related Studies:
Other Coronary Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
Modifying Oxidative Damage in WAVE - Ancillary to WAVE
|
|
|
|
|
|
|
|
